pharma news today glp-1 obesity drug Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat and other weight-related conditions Lilly launches GLP-1 pill, kicking

The Rise of GLP-1 Receptor Agonists in Australia & AI's Transformative Role The Australian market for GLP-1 receptor agonists is poised for substantial expansion, driven by the increasing prevalence of type 2 diabetes and obesity

Circulation 148 , 16061635 (2023)

The drugs have shown benefits beyond weight loss, such as for heart health and sleep apnea, but their side effects can include severe gastrointestinal symptoms and rare incidents of pancreatitis, depression and blindness

Its important to understand that for Wegovy, only the marked doses on the single-use, fixed-dose pens are approved for use and represent an authentic FDA-approved medicine. Eli Lilly says it doesnt have any data on the benefits or risks of microdosing tirzepatide, the active ingredient in Zepbound and Mounjaro

To generate Dpp4 hep/ mice, Dpp4 fl/fl adult mice, provided by Merck Research Laboratories (38), were i.v